Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 4/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696307 | 1.00 | TRPV1 (0.46) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL22925584 | 0.89 | TRPV1 (0.42) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL29621024 | 0.89 | VCP (0.47) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL29620983 | 0.89 | TRPV1 (0.42) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL22925864 | 0.89 | VCP (0.47) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL22925589 | 0.87 | VCP (0.43) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL29620919 | 0.87 | VCP (0.43) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL22925579 | 0.86 | TRPV1 (0.41) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL29621009 | 0.86 | TRPV1 (0.41) | TRPV1ALOX5VCPDGAT1FLT1 | |
| SCHEMBL22925576 | 0.86 | TRPV1 (0.47) | TRPV1ALOX5VCPDGAT1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | TRPV1 4690/4885ALOX5 1469/4885VCP 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.